EyePoint Pharmaceuticals Reports 97% Revenue Decline and $84.8 Million Net Loss in Q1 2026

EyePoint Pharmaceuticals, Inc. reported a significant decline in financial performance for the first quarter of 2026, with total revenues falling to $696,000, a decrease of 97% compared to $24.5 million in the same period of 2025. The drop was primarily driven by a 99% reduction in license and collaboration agreement revenues, which fell to $88,000 from $11 million, and a similar decline in royalty income, which decreased to $141,000 from $12.7 million. Product sales also decreased by 35% to $467,000, attributed to the termination of the ANI commercial supply agreement in 2025.

Operating expenses increased by 20% to $87.9 million, up from $73.3 million in the prior year. This rise was largely due to a 23% increase in research and development expenses, which reached $72.1 million, reflecting ongoing Phase 3 clinical trials for the company's lead product candidate, DURAVYU, aimed at treating retinal diseases. General and administrative expenses also rose by 10% to $15.2 million, driven by higher personnel costs, including stock-based compensation. The net loss for the quarter was $84.8 million, compared to a loss of $45.2 million in the same quarter of 2025, resulting in a net loss per share of $0.99, up from $0.65.

In terms of strategic developments, EyePoint announced the appointment of Michael Campbell as Chief Commercial Officer in February 2026. The company is actively pursuing its lead product, DURAVYU, which is currently in pivotal Phase 3 trials for wet age-related macular degeneration and diabetic macular edema, with data readouts expected to begin in mid-2026. Additionally, EyePoint reached an agreement in principle with the U.S. Department of Justice to settle ongoing investigations related to its sales and marketing practices, which includes a payment of approximately $4.7 million.

Operationally, EyePoint's cash, cash equivalents, and marketable securities totaled $222.5 million as of March 31, 2026, providing a runway to fund operations into the fourth quarter of 2027. The company has a history of operating losses and relies on equity financing and collaboration agreements for funding. As of the end of the first quarter, EyePoint had 83.5 million shares outstanding, an increase from 82.8 million at the end of 2025. The company anticipates continued losses as it advances its clinical programs and seeks regulatory approvals for its product candidates.

Looking ahead, EyePoint remains focused on the development of DURAVYU and other pipeline candidates, while also navigating the complexities of regulatory compliance and potential settlements related to ongoing investigations. The company expects to continue incurring significant operating losses and will assess its funding needs as it progresses through clinical trials and prepares for potential commercialization of its products.